2017 News Releases

News Releases | Events
Webcast ImageWebcast
Axsome Therapeutics at Ladenburg Thalmann Healthcare Conference  (Live)
September 26, 2017 at 9:30 a.m. ET
Axsome Therapeutics at Ladenburg Thalmann Healthcare Conference
Tuesday, September 26, 2017 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Axsome Therapeutics at Cantor Fitzgerald Global Healthcare Conference (Live)
September 27, 2017 at 1:40 p.m. ET
Axsome Therapeutics at Cantor Fitzgerald Global Healthcare Conference
Wednesday, September 27, 2017 1:40 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
Axsome Therapeutics to Present at Upcoming Investor ConferencesSeptember 18, 2017NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the following investor conferences: The Ladenburg Thalmann 2017 Healthcare Conference in New York, NY on Tuesday, September 26, 2017 at 9:30 AM Eastern Time. ... Read MoreAxsome Announces CREATE-1 Interim Analysis Expected Year-End 2017September 7, 2017Interim analysis results for both CREATE-1 and COAST-1 trials anticipated late December to early January NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the interim efficacy analysis of the Phase 3 CREATE-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017. The interim ana... Read MoreAxsome Therapeutics Reports Second Quarter 2017 Financial ResultsAugust 9, 2017NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended June 30, 2017. “We continued our forward momentum in the second quarter with the expansion of our clinical programs as well as our team,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome. “Our clinical pipelin... Read MoreAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical TrialJuly 25, 2017AXS-06 is an oral, rapidly-absorbed, once-daily, non-opioid, COX-2 preferential pain therapeutic with a gastroprotectant Primary endpoint met with 9 times faster time to maximum plasma concentration (Tmax) of meloxicam versus Mobic® (p<0.0001) Therapeutic plasma levels of meloxicam achieved within 15 minutes of oral dosing of AXS-06 Gastroprotective concentrations of esomeprazole achieved  Phase 3-ready based on FDA Pre-IND guidance AXS-06 utilizes Axsome’s MoSEIC™ delivery technology... Read MoreAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease AgitationJuly 17, 2017First patient enrolled in the ADVANCE-1 study Agitation reported in nearly 50% of patients with Alzheimer’s disease FDA Fast Track designation previously received for AXS-05 for Alzheimer’s disease agitation Second indication for AXS-05 in late-stage clinical trials NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolle... Read MoreAxsome Therapeutics Appoints John Golubieski as Chief Financial OfficerJuly 6, 2017NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of John Golubieski as Chief Financial Officer, effective August 4, 2017. “John is an accomplished, results-oriented, financial executive who has held leadership roles in large multinational and specialty pharmaceutical companies,” said Herriot Ta... Read MoreAxsome Therapeutics Appoints Myrtle Potter to its Board of DirectorsJune 19, 2017NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is the Chief Executive Officer and Founder of Myrtle Potter & Company, a healthcare and life science advisory firm. Ms. Potter previously served as the President, Commercial Operations and Chief... Read MoreAxsome Therapeutics Reports First Quarter 2017 Financial ResultsMay 9, 2017NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended March 31, 2017. “In the first quarter we continued to advance all of our clinical programs, which include three ongoing Phase 3 trials with our lead product candidates AXS-02 and AXS-05,” said Herriot Tabuteau, M.D., Chief E... Read MoreAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease AgitationMay 8, 2017NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for AXS-05 for the treatment of agitation in patients with Alzheimer’s disease (AD). There are currently no approved treatments for this condition. Axsome previously received Investigational New Drug A... Read MoreAxsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional SharesMarch 29, 2017NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the underwriter of the Company’s previously announced public offering has exercised in full its option to purchase an additional 561,497 shares. With the exercise of the underwriter’s option, total gross proceeds from the offering of an aggregate 4,304,813 sh... Read MoreAxsome Therapeutics to Present at the 16th Annual Needham Healthcare ConferenceMarch 23, 2017NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on April 5, 2017 at 8:40 AM Eastern Time. The conference will be held at The Westin NY Grand Central Hotel in New York... Read MoreAxsome Therapeutics Announces Pricing of Its Public Offering of Common StockMarch 21, 2017NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering of 3,743,316 shares of its common stock at a public offering price of $3.74 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses... Read MoreAxsome Therapeutics Announces Proposed Public Offering of Common StockMarch 20, 2017NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Axsome intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offer... Read MoreAxsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateMarch 7, 2017Interim analysis results from two Phase 3 trials of AXS-02 in separate indications anticipated in 2H 2017 Top-line results from the Phase 3 STRIDE-1 trial of AXS-05 in treatment resistant depression expected in 1Q 2018 Phase 2/3 trial of AXS-05 in Alzheimer’s disease agitation to begin in 2Q 2017 NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous sys... Read MoreAxsome Therapeutics to Present at the 29th Annual ROTH ConferenceFebruary 27, 2017NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 29th Annual ROTH Conference on March 14, 2017 at 8:30 AM Pacific Time. The conference will be held at the The Ritz-Carlton, Laguna Niguel in Dana Point, CA. A l... Read MoreAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionFebruary 14, 2017NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for AXS-05 for treatment resistant depression (TRD). AXS-05 is currently being evaluated in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial to assess the efficacy and ... Read MoreAxsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare ConferenceFebruary 13, 2017NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 2017 RBC Capital Markets Global Healthcare Conference on February 23, 2017 at 11:30 AM Eastern Time. The conference will be held at the New York Palace in New Yo... Read MoreAxsome Therapeutics to Present at the 2017 BIO CEO & Investor ConferenceFebruary 7, 2017NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 2017 BIO CEO & Investor Conference on February 14th, 2017 at 9:00 AM Eastern Time. The conference will be held at the Waldorf Astoria New York in New York, NY. ... Read MoreAxsome Therapeutics to Present at Biotech Showcase 2017January 4, 2017NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 9th Annual Biotech Showcase 2017 conference on January 9, 2017 at 10:30 AM Pacific Time. The conference will be held at the Hilton San Francisco Union Square in ... Read MoreAxsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationJanuary 3, 2017NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its Investigational New Drug Application (IND) for AXS-05 in the treatment of agitation in patients with Alzheimer’s disease (AD) has been cleared by the U.S. Food and Drug Administration (FDA). The IND clearance permits Axsome to proceed with its planned Phas... Read More
Print PageE-mail PageRSS FeedsE-mail AlertsFinancial Tear Sheet